Personalized Dendritic Cell Vaccines Could Improve Cancer Immunotherapy – Genetic Engineering & Biotechnology News
Genetic Engineering & Biotechnology News |
Personalized Dendritic Cell Vaccines Could Improve Cancer Immunotherapy
Genetic Engineering & Biotechnology News Dendritic cell vaccines, a promising cancer immunotherapy approach, usually come from dendritic cells that have been force-fed with tumor antigens. Dendritic cells, however, can also be modified so that they gorge themselves on antigen-carrying … ‘Cross-dressing’ cells may improve cancer treatmentInfosurhoy |
The Daily Cardinal |
Biological Industries USA Announces Mesenchymal Stromal and Stem Cell Research Award, Including Conference …
Business Wire (press release) CROMWELL, Conn. & BOSTON–(BUSINESS WIRE)–Biological Industries USA (BI-USA), the North American commercial division of Biological Industries, one of the world’s leading suppliers to the life sciences industry, is proud to announce the BI-USA … New stem cell method aids heart disease researchThe Daily Cardinal Stem Cell Therapy treats ailments in the body due to aging and other common problemsGood4Utah Researchers create first stem cells using CRISPR genome activationDrug Target Review GlobeNewswire (press release) –Nasdaq –UroToday all 54 news articles » |
FierceBiotech |
Tmunity nabs $100M for next-gen T-cell immunotherapies
FierceBiotech The funding comes from the likes of Ping An Ventures, the Parker Institute for Cancer Immunotherapy, Gilead, the University of Pennsylvania and Lilly Asia Ventures. The “unprecedented” expertise and level of scientific thinking in the founders and … Xconomy: Tmunity Reels in $100M for “Next Generation” Cancer …Xconomy Gilead, Parker Institute grab stakes in Penn immunotherapy spinout’s $100 million roundSan Francisco Business Times Carl June’s Cancer Startup Raises $100 Million From Gilead, Sean …Forbes Philly.com (blog) all 12 news articles » |
Healthline |
My Two-Decade Journey with Cancer Immunotherapy
Healthline While cancer patients have relied on surgery, chemotherapy, and radiotherapy seemingly forever, immunotherapy has come of age. It’s now one of the leading wings of cancer drug development, and easily the most written about in the past few years. Among … |
|
Allied with Penn, Tmunity’s cell therapy pioneers bag $100M mega-round to back a breakthrough quest on CAR–T …
Endpoints News Novartis vet Usman “Oz” Azam and Penn researcher Carl June are two of the ultimate insiders in the CAR–T revolution. They each played prominent roles in advancing Novartis’ breakthrough therapy Kymriah to an historic first-ever approval. They are now … |
Xconomy |
Tmunity Reels in $100M for “Next Generation” Cancer Immunotherapy
Xconomy Two therapies from the emerging field of engineered T cells won FDA approval to treat blood cancers last year, and the scramble is on to treat more types of cancer. Led by Usman “Oz” Azam (pictured above), the executive who once led Novartis’s cell and … Tmunity nabs $100M for next-gen T-cell immunotherapiesFierceBiotech Penn immunotherapy spin-out raises $100MPhiladelphia Business Journal Cancer startup TMunity raises $100 million to advance next-generation T cell Immunotherapies to transform the …TechStartups.com (blog) Business Wire (press release) –Forbes –Philly.com (blog) all 8 news articles » |